EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

Maria F Mojica iD, Elise T Zeiser iD, Scott A Becka, John J LiPuma iD, David A Six iD, Greg Moeck, Krisztina M Papp-Wallace iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00498-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Maria F Mojica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Burkholderia gladioli, Burkholderia cepacia complex, Cystic Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Burkholderia gladioli strains. The addition of taniborbactam to cefepime shifted cefepime minimum inhibitory concentrations toward the provisionally susceptible range in 59% of the isolates tested. Therefore, cefepime-taniborbactam possessed similar activity as first-line agents, ceftazidime and trimethoprim-sulfamethoxazole, supporting further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkholderia gladioliBurkholderia cepacia complexCystic FibrosisHumansUnited StatesCefepimeAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesMicrobial Sensitivity TestsBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

BurkholderiaPenAcarbapenemasecefepime-taniborbactamβ-lactamβ-lactamase inhibitorβ-lactamases

Substanzen

CefepimeAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasestaniborbactamBorinic AcidsCarboxylic Acids

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio, USA.
  • Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA.
  • CASE-VA Center for Antimicrobial Resistance and Epidemiology , Cleveland, Ohio, USA.
  • University of Michigan , Ann Arbor, Michigan, USA.
  • Venatorx Pharmaceuticals, Inc. , Malvern, Pennsylvania, USA.
  • Department of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.

ORCID-Profile: Maria F Mojica, Elise T Zeiser, John J LiPuma, David A Six, Krisztina M Papp-Wallace

Förderung

  • Wellcome Trust
  • NIAID NIH HHS
  • BLRD VA
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • U.S. Department of Health and Human Services
  • U.S. Department of Veterans Affairs
  • Cystic Fibrosis Foundation

Zitieren

APA

Mojica, M. F., Zeiser, E. T., Becka, S. A., LiPuma, J. J., Six, D. A., Moeck, G., & Papp-Wallace, K. M. (2023). Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00498-23

Vancouver

Mojica MF, Zeiser ET, Becka SA, LiPuma JJ, Six DA, Moeck G, et al. Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00498-23

BibTeX
@article{Mojica2023,
  author = {Mojica, Maria F and Zeiser, Elise T and Becka, Scott A and LiPuma, John J and Six, David A and Moeck, Greg and Papp-Wallace, Krisztina M},
  title = {Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00498-23}
}
Kostenlos starten →